– Lead program, GT-2108 for the treatment of moderate-to-severe ulcerative colitis advancing toward completion of I ND-enabling studies with IND filing expected

PALI

Veon Received Russian Regulatory Approval For The Proposed Sale Of Its Russian Operations

By Benzinga Newsdesk

February 8, 3:35 AM

VEON Ltd. (NASDAQ:VEON, Euronext Amsterdam: VEON)))), a global digital operator that provides converged connectivity and online services, today announces that approval has been received from Russian regulatory bodies for

VEON

Longbow Research Downgrades Stanley Black & Decker to Neutral

Related Posts

Baird Maintains Neutral on Fleetcor Technologies, Raises Price Target to $230

Baird Maintains Outperform on Homology Medicines, Lowers Price Target to $9

Palisade Bio Transforms GI-Focused Pipeline Through Exclusive Worldwide Licensing Agreement With Giiant Pharma, Inc. For Multiple Oral Drug Candidates Targeting Inflammatory Bowel Disease

Veon Received Russian Regulatory Approval For The Proposed Sale Of Its Russian Operations